News & Events

February 13, 2025

Press release | LabGenius Therapeutics Appoints Three Experts to its Team of Scientific Advisors

Upcoming Events

Mar 17

Bio-Europe Spring

Apr 1

BioTrinity

Apr 29

LSX World Congress

May 12

PEGS Boston

January 17, 2024

Podcast | T-Cell Engagers: The New Cancer Drug?

December 22, 2023

Blog | Q&A with Mohammad Akhlaq, Head of Automation at LabGenius

November 15, 2023

Feature | BBC News covers LabGenius and how it harnesses AI in the search for new medicines

November 9, 2023

Podcast | LabGenius’ CEO, James Field, discusses ML-enabled drug discovery with Patrick Short on the Genetics Podcast

October 19, 2023

Report | The Life Sciences Future50

September 27, 2023

Podcast | Leveraging Generative AI to Design Therapeutic Antibodies

September 18, 2023

Press release | LabGenius’ Research Collaboration with Sanofi Yields Positive Results

September 18, 2023

Article | Questions Every VC Needs to Ask About Every AI Startup’s Tech Stack

September 18, 2023

Article | Machine Learning Enhances Antibody Discovery: A Glimpse into LabGenius and Sanofi’s Collaborative Endeavour

August 9, 2023

Article | AI is Building Highly Effective Antibodies That Humans Can’t Even Imagine

July 7, 2023

Podcast | LabGenius’ CEO, James Field, discusses ML-enabled drug discovery as a recent guest on the Business of Biotech podcast

May 15, 2023

Press release | LabGenius Debuts T-cell Engager Optimisation Capability That Yields Molecules with >400-fold Tumour Killing Selectivity Versus Clinical Benchmark